-
1
-
-
0033503797
-
Intrahepatic recurrence after curative resection of hepatocellular carcinoma: Long-term results of treatment and prognostic factors
-
Poon R, Fan S, Lo C, Wang J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216-222.
-
(1999)
Ann Surg
, vol.229
, pp. 216-222
-
-
Poon, R.1
Fan, S.2
Lo, C.3
Wang, J.4
-
2
-
-
33846631323
-
Radiofrequency ablation of hepatocellular carcinoma: Correlation between local tumor progression after ablation and ablative margin
-
Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR 2007; 188:480-488.
-
(2007)
AJR
, vol.188
, pp. 480-488
-
-
Nakazawa, T.1
Kokubu, S.2
Shibuya, A.3
Ono, K.4
Watanabe, M.5
Hidaka, H.6
-
3
-
-
40149087561
-
Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: Risk factors and patterns
-
Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol 2008; 43:71-78.
-
(2008)
J Gastroenterol
, vol.43
, pp. 71-78
-
-
Okuwaki, Y.1
Nakazawa, T.2
Shibuya, A.3
Ono, K.4
Hidaka, H.5
Watanabe, M.6
-
4
-
-
72049103667
-
Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma
-
Okuwaki Y, Nakazawa T, Kokubu S, Hidaka H, Tanaka Y, Takada J, et al. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma. Am J Gastroenterol 2009; 104:2747-2753.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 2747-2753
-
-
Okuwaki, Y.1
Nakazawa, T.2
Kokubu, S.3
Hidaka, H.4
Tanaka, Y.5
Takada, J.6
-
5
-
-
77749298647
-
Liver cancer study group of Japan overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: Propensity score analysis
-
Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, et al. Liver cancer study group of Japan overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR 2010; 194:830-837.
-
(2010)
AJR
, vol.194
, pp. 830-837
-
-
Takayasu, K.1
Arii, S.2
Ikai, I.3
Kudo, M.4
Matsuyama, Y.5
Kojiro, M.6
-
6
-
-
0036682065
-
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: Analysis of 48 cases
-
Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95:588-595.
-
(2002)
Cancer
, vol.95
, pp. 588-595
-
-
Ando, E.1
Tanaka, M.2
Yamashita, F.3
Kuromatsu, R.4
Yutani, S.5
Fukumori, K.6
-
7
-
-
41549135296
-
Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels
-
Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, et al. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels. Oncology 2007; 73:90-97.
-
(2007)
Oncology
, vol.73
, pp. 90-97
-
-
Nakazawa, T.1
Adachi, S.2
Kitano, M.3
Isobe, Y.4
Kokubu, S.5
Hidaka, H.6
-
8
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
-
9
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebocontrolled trial
-
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009; 10:25-34.
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
Tsao, C.J.4
Qin, S.5
Kim, J.S.6
-
10
-
-
4944249117
-
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
-
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
-
(2004)
Cancer Res
, vol.64
, pp. 7099-7109
-
-
Wilhelm, S.M.1
Carter, C.2
Tang, L.3
Wilkie, D.4
McNabola, A.5
Rong, H.6
-
12
-
-
47649105803
-
Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma
-
Toyoda H, Kumada T, Osaki Y, Oka H, Kudo M. Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res 2007; 37:S166-S171.
-
(2007)
Hepatol Res
, vol.37
-
-
Toyoda, H.1
Kumada, T.2
Osaki, Y.3
Oka, H.4
Kudo, M.5
-
13
-
-
60049099362
-
High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma
-
Kobayashi M, Ikeda K, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115:571-580.
-
(2009)
Cancer
, vol.115
, pp. 571-580
-
-
Kobayashi, M.1
Ikeda, K.2
Kawamura, Y.3
Yatsuji, H.4
Hosaka, T.5
Sezaki, H.6
-
14
-
-
58749090909
-
New utility of an old marker: Serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy
-
Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27:446-452.
-
(2009)
J Clin Oncol
, vol.27
, pp. 446-452
-
-
Chan, S.L.1
Mo, F.K.2
Johnson, P.J.3
Hui, E.P.4
Ma, B.B.5
Ho, W.M.6
-
15
-
-
84355167145
-
Rapid regression of advanced hepatocellular carcinoma associated with elevation of desgamma-carboxy prothrombin after short-term treatment with sorafenib-A report of two cases
-
Nakazawa T, Hidaka H, Shibuya A, Koizumi W. Rapid regression of advanced hepatocellular carcinoma associated with elevation of desgamma-carboxy prothrombin after short-term treatment with sorafenib-a report of two cases. Case Rep Oncol 2010; 3:298-303.
-
(2010)
Case Rep Oncol
, vol.3
, pp. 298-303
-
-
Nakazawa, T.1
Hidaka, H.2
Shibuya, A.3
Koizumi, W.4
-
16
-
-
77957559384
-
Early alphafetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
-
Shao YY, Lin ZZ, Hsu C, Shen YC, Hsu CH, Cheng AL. Early alphafetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116:4590-4596.
-
(2010)
Cancer
, vol.116
, pp. 4590-4596
-
-
Shao, Y.Y.1
Lin, Z.Z.2
Hsu, C.3
Shen, Y.C.4
Hsu, C.H.5
Cheng, A.L.6
-
17
-
-
79551521168
-
Early a-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma
-
Kim BK, Ahn SH, Seong JS, Park JY, Kim do Y, Kim JK, et al. Early a-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int 2011; 31:369-376.
-
(2011)
Liver Int
, vol.31
, pp. 369-376
-
-
Kim, B.K.1
Ahn, S.H.2
Seong, J.S.3
Park, J.Y.4
Kim Do, Y.5
Kim, J.K.6
-
18
-
-
80051745537
-
Des-g-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma
-
Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, et al. Des-g-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011; 29:321-325.
-
(2011)
Dig Dis
, vol.29
, pp. 321-325
-
-
Ueshima, K.1
Kudo, M.2
Takita, M.3
Nagai, T.4
Tatsumi, C.5
Ueda, T.6
-
19
-
-
81555231534
-
Early decrease in a-fetoprotein, but not des-g-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma
-
Kuzuya T, Asahina Y, Tsuchiya K, Tanaka K, Suzuki Y, Hoshioka T, et al. Early decrease in a-fetoprotein, but not des-g-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 2011; 81:251-258.
-
(2011)
Oncology
, vol.81
, pp. 251-258
-
-
Kuzuya, T.1
Asahina, Y.2
Tsuchiya, K.3
Tanaka, K.4
Suzuki, Y.5
Hoshioka, T.6
-
20
-
-
34249322375
-
Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13772 patients in Japan
-
Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13772 patients in Japan. Ann Surg 2007; 245:909-922.
-
(2007)
Ann Surg
, vol.245
, pp. 909-922
-
-
Minagawa, M.1
Ikai, I.2
Matsuyama, Y.3
Yamaoka, Y.4
Makuuchi, M.5
-
21
-
-
44449085884
-
Panel of experts in HCC-design clinical trials: Design and endpoints of clinical trials in hepatocellular carcinoma
-
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Panel of experts in HCC-design clinical trials: design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698-711.
-
(2008)
J Natl Cancer Inst
, vol.100
, pp. 698-711
-
-
Llovet, J.M.1
Di Bisceglie, A.M.2
Bruix, J.3
Kramer, B.S.4
Lencioni, R.5
Zhu, A.X.6
-
22
-
-
57849117384
-
New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
23
-
-
77349102071
-
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
-
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60.
-
(2010)
Semin Liver Dis
, vol.30
, pp. 52-60
-
-
Lencioni, R.1
Llovet, J.M.2
-
24
-
-
67651165187
-
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: An open-label, multicentre, phase II study
-
Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10:794-800.
-
(2009)
Lancet Oncol
, vol.10
, pp. 794-800
-
-
Faivre, S.1
Raymond, E.2
Boucher, E.3
Douillard, J.4
Lim, H.Y.5
Kim, J.S.6
-
25
-
-
67649946279
-
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma; A phase II study
-
Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma; a phase II study. J Clin Oncol 2009; 27:3027-3035.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3027-3035
-
-
Zhu, A.X.1
Sahani, D.V.2
Duda, D.G.3
Di Tomaso, E.4
Ancukiewicz, M.5
Catalano, O.A.6
-
26
-
-
47649124110
-
Clinical significance of alpha-fetoprotein: Involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma
-
Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, et al. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23:e189-e197.
-
(2008)
J Gastroenterol Hepatol
, vol.23
-
-
Mitsuhashi, N.1
Kobayashi, S.2
Doki, T.3
Kimura, F.4
Shimizu, H.5
Yoshidome, H.6
-
27
-
-
36549061592
-
Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan
-
Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38:37-51.
-
(2008)
Hepatol Res
, vol.38
, pp. 37-51
-
-
Makuuchi, M.1
Kokudo, N.2
Arii, S.3
Futagawa, S.4
Kaneko, S.5
Kawasaki, S.6
-
28
-
-
78651317489
-
AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC
-
Yamamoto K, Imamura H, Matsuyama Y, Kume Y, Ikeda H, Norman GL, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol 2010; 45:1272-1282.
-
(2010)
J Gastroenterol
, vol.45
, pp. 1272-1282
-
-
Yamamoto, K.1
Imamura, H.2
Matsuyama, Y.3
Kume, Y.4
Ikeda, H.5
Norman, G.L.6
-
29
-
-
74549217434
-
Hypoxiainduced des-gamma-carboxy prothrombin production in hepatocellular carcinoma
-
Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Hypoxiainduced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2010; 36:161-170.
-
(2010)
Int J Oncol
, vol.36
, pp. 161-170
-
-
Murata, K.1
Suzuki, H.2
Okano, H.3
Oyamada, T.4
Yasuda, Y.5
Sakamoto, A.6
-
30
-
-
0024306506
-
Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin
-
Liebman HA. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy) prothrombin. Cancer Res 1989; 49:6493-6497.
-
(1989)
Cancer Res
, vol.49
, pp. 6493-6497
-
-
Liebman, H.A.1
-
31
-
-
33644693140
-
Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma
-
Uehara S, Gotoh K, Handa H, Tomita H, Senshuu M. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2005; 20:1545-1552.
-
(2005)
J Gastroenterol Hepatol
, vol.20
, pp. 1545-1552
-
-
Uehara, S.1
Gotoh, K.2
Handa, H.3
Tomita, H.4
Senshuu, M.5
-
32
-
-
70449579247
-
Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma
-
Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2009; 35:1005-1014.
-
(2009)
Int J Oncol
, vol.35
, pp. 1005-1014
-
-
Murata, K.1
Suzuki, H.2
Okano, H.3
Oyamada, T.4
Yasuda, Y.5
Sakamoto, A.6
-
33
-
-
84856082759
-
Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: A case report
-
Okuwaki Y, Nakazawa T, Hidaka H, Shibuya S, Koizumi W. Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. J Med Case Rep 2012; 6:38.
-
(2012)
J Med Case Rep
, vol.6
, pp. 38
-
-
Okuwaki, Y.1
Nakazawa, T.2
Hidaka, H.3
Shibuya, S.4
Koizumi, W.5
|